Takeda logo

Awny Farajallah, M.D. | Head of Global Medical Affairs Oncology | Takeda Oncology

Profile Section

Awny Farajallah, M.D.

Chief Medical Officer, Global Oncology Business Unit


Awny Farajallah, M.D. is the Chief Medical Officer for the Global Oncology Business Unit (GOBU), spearheading the development of our expanded inline portfolio.

Awny joined Takeda in July 2021 as the Head of Global Medical Affairs Oncology. He is a strategic leader with over 25 years of combined experience in both academic and industry settings related to clinical research/development and medical affairs across multiple therapeutic areas.

Before joining Takeda, Awny worked at Ipsen, where he was Senior Vice President, Medical Affairs, North America. As a key North America Leadership Team and Global Medical Affairs Leadership Team member, Awny was responsible for providing strategic leadership and direction for all facets of the Medical Affairs organization in North America. During his tenure, Awny also led efforts to enhance Medical Affairs capabilities with the goal of broadening the impact to patients through medical stakeholder partnerships across Oncology, Neuroscience and Rare Disease.

Prior to joining Ipsen, Awny served as Vice President and Head of US Medical Affairs at Bristol Myers Squibb, where he led functions such as field medical, disease areas, medical education, biomarkers, promotional material review, portfolio strategy, as well as strategic collaborations across oncology, immunoscience, cardiovascular, neurology and mature brands. Awny has led multiple successful launches in Immuno-oncology and hematology for Opdivo® and Yervoy® and Sprycel®. He also was the clinical development lead for hematological malignancies in leukemia and multiple myeloma. He also led the global medical and clinical development teams for HIV including Reyataz® global life cycle management and business development.

Awny earned his M.D. from Cairo University and completed an Internal Medicine residency and Infectious Diseases fellowship at the University of Arkansas for Medical Sciences and New Jersey Medical School, respectively.

All trademarks are the property of their respective owners.

©2024 Takeda Pharmaceuticals U.S.A., Inc.

All rights reserved.   01/23